William Tester

4.1k total citations · 1 hit paper
72 papers, 2.7k citations indexed

About

William Tester is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, William Tester has authored 72 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 25 papers in Surgery. Recurrent topics in William Tester's work include Lung Cancer Treatments and Mutations (16 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Cancer Treatment and Pharmacology (10 papers). William Tester is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Cancer Treatment and Pharmacology (10 papers). William Tester collaborates with scholars based in United States, Canada and Spain. William Tester's co-authors include William U. Shipley, Leonard E. Braitman, Etienne Phipps, Diana Harris, Donald S. Kaufman, Peter Venner, John Heaney, Michael P. Hagan, Niall M. Heney and David H. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

William Tester

67 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233

2014 294 citations Raymond H. Mak, Daniel Hunt et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Tester United States	22	1.2k	818	699	472	390	72	2.7k
Stephan Roth Germany	25	1.2k 1.0×	400 0.5×	452 0.6×	635 1.3×	170 0.4×	150	2.1k
Sandra Turner Australia	28	958 0.8×	470 0.6×	1.7k 2.4×	139 0.3×	195 0.5×	109	2.9k
Erik P. Castle United States	37	2.0k 1.7×	593 0.7×	2.0k 2.9×	933 2.0×	275 0.7×	163	4.0k
Sarah P. Psutka United States	29	1.4k 1.2×	761 0.9×	1.7k 2.4×	223 0.5×	124 0.3×	184	3.5k
G. Carmignani Italy	33	1.3k 1.2×	298 0.4×	1.2k 1.6×	841 1.8×	172 0.4×	189	3.1k
D. Andrew Loblaw Canada	14	772 0.7×	379 0.5×	1.1k 1.5×	182 0.4×	113 0.3×	32	2.0k
Armin Pycha Italy	37	3.1k 2.7×	584 0.7×	776 1.1×	1.5k 3.2×	89 0.2×	141	4.3k
Sandra Goble United States	22	633 0.5×	693 0.8×	135 0.2×	249 0.5×	174 0.4×	66	1.9k
Richard G. Middleton United States	31	983 0.8×	420 0.5×	2.1k 3.0×	413 0.9×	281 0.7×	107	3.4k
Michael P. Porter United States	27	1.6k 1.3×	604 0.7×	669 1.0×	813 1.7×	83 0.2×	64	2.5k

Countries citing papers authored by William Tester

Since Specialization

Citations

This map shows the geographic impact of William Tester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Tester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Tester more than expected).

Fields of papers citing papers by William Tester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Tester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Tester. The network helps show where William Tester may publish in the future.

Co-authorship network of co-authors of William Tester

This figure shows the co-authorship network connecting the top 25 collaborators of William Tester. A scholar is included among the top collaborators of William Tester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Tester. William Tester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zorko, Nicholas A., Biren Saraiya, William Tester, et al.. (2025). Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.. Journal of Clinical Oncology. 43(5_suppl). 128–128.

Ghatalia, Pooja, Eric A. Ross, Matthew R. Zibelman, et al.. (2025). A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).. Journal of Clinical Oncology. 43(5_suppl). 815–815. 2 indexed citations

Mille, Patrick, et al.. (2024). Tumor-associated antigen targets for novel immune-based strategies in prostate cancer. 8(1). 55–76. 1 indexed citations

Zarrabi, Kevin, et al.. (2024). Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. Molecules. 29(8). 1896–1896. 8 indexed citations

Fong, Lawrence, Mohamad A. Salkeni, Anthony B. El-Khoueiry, et al.. (2024). ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e14681–e14681. 1 indexed citations

Subudhi, Sumit K., Gerald S. Falchook, Mohamad A. Salkeni, et al.. (2023). 759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors. SHILAP Revista de lepidopterología. A855–A855.

Steuer, Conor, Opeyemi A. Jegede, Suzanne E. Dahlberg, et al.. (2021). Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. Journal of Thoracic Oncology. 16(6). 960–967. 8 indexed citations

Magliocco, Anthony, Jennifer Moughan, Jeffry Simko, et al.. (2017). The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.. International Journal of Radiation Oncology*Biology*Physics. 99(2). S117–S118. 5 indexed citations

Mak, Raymond H., Daniel Hunt, William U. Shipley, et al.. (2014). Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of Clinical Oncology. 32(34). 3801–3809. 294 indexed citations breakdown →

10.

Dutcher, Janice P., Donna Neuberg, Michael B. Atkins, et al.. (2014). Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution. Journal of Interferon & Cytokine Research. 34(5). 376–384. 3 indexed citations

11.

Chae, Young Kwang, et al.. (2012). Association between Common Allergic Symptoms and Cancer in the NHANES III Female Cohort. PLoS ONE. 7(9). e42896–e42896. 8 indexed citations

12.

Valsecchi, Matías E., Sherry Pomerantz, Rebecca Jaslow, & William Tester. (2009). Reduced Risk of Bone Metastasis for Patients With Breast Cancer Who Use COX-2 Inhibitors. Clinical Breast Cancer. 9(4). 225–230. 23 indexed citations

13.

Phipps, Etienne, et al.. (2008). The Importance of Patient Participation in Second-Line Chemotherapy Decisions: Perspectives of African-American Patients. Journal of the National Medical Association. 100(12). 1434–1440. 7 indexed citations

14.

Tester, William, et al.. (2006). Phase I/II Study of Weekly Docetaxel and Vinblastine in the Treatment of Metastatic Hormone-Refractory Prostate Carcinoma. The Cancer Journal. 12(4). 299–304. 10 indexed citations

15.

Chakravarti, Arnab, Kathryn Winter, Chin‐Lee Wu, et al.. (2005). Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. International Journal of Radiation Oncology*Biology*Physics. 62(2). 309–317. 115 indexed citations

16.

Tester, William, et al.. (2001). Innovative treatments for. Expert Opinion on Investigational Drugs. 10(6). 1021–1032. 2 indexed citations

17.

Kerr, Robert O., et al.. (1997). Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management. 14(2). 63–73. 58 indexed citations

18.

Tester, William, Richard Caplan, John Heaney, et al.. (1996). Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.. Journal of Clinical Oncology. 14(1). 119–126. 201 indexed citations

19.

Asbell, Sucha O., Shalom A. Leon, William Tester, et al.. (1996). Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. The Prostate. 29(4). 243–248. 41 indexed citations

20.

Tester, William, Arthur T. Porter, Sucha O. Asbell, et al.. (1993). Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12. International Journal of Radiation Oncology*Biology*Physics. 25(5). 783–790. 200 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact